Therapeutics Acquisition Corp. | Uncategorized | Business Contracts

Fourth Amendment dated May 6, 2022 to Exclusive Sublicense Agreement dated April 2, 2020 (Filed With SEC on August 12, 2022)

Description of Securities (Filed With SEC on March 25, 2022)

Sublicense Agreement dated November 14, 2019 between POINT Theranostics Inc. and Scintomics GmbH (Filed With SEC on March 25, 2022)

Revised Form of Non (Filed With SEC on December 10, 2021)

Revised Form of (Filed With SEC on December 10, 2021)

Exclusive Sublicense Agreement, dated April 2, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

First Amendment to Exclusive Sublicense Agreement, dated April 14, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Second Amendment to Exclusive Sublicense Agreement, dated January 5, 2021 to be effective as of December 31, 2020, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Third Amendment to Exclusive Sublicense Agreement, dated September 24, 2021, between Bach Biosciences, LLC and POINT Biopharma Inc (Filed With SEC on November 12, 2021)

Description of the Companys securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on March 4, 2021)

Letter Agreement, dated July 7, 2020, by and among the Company, its officers, its directors and Therapeutics Acquisition Holdings, LLC (Filed With SEC on July 10, 2020)

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant (Filed With SEC on July 6, 2020)

Specimen Unit Certificate (Filed With SEC on June 15, 2020)

Form of Indemnity Agreement (Filed With SEC on June 15, 2020)

Form of Letter Agreement among the Registrant and each director and executive officer of the Registrant (Filed With SEC on June 15, 2020)

Therapeutics Acquisition Corp. (59) | Uncategorized (15)